⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SRPT News
Sarepta Therapeutics,, Inc. Common Stock
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
businesswire.com
SRPT
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
businesswire.com
SRPT
Sarepta Provides Regulatory Update on AMONDYS 45 ® and VYONDYS 53 ®
businesswire.com
SRPT
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
businesswire.com
SRPT
Amondys 45 (casimersen: Sarepta Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
SRPT
PPMD Joins Cooperative International Neuromuscular Research Group, Global Sponsors to Advance Expanded Duchenne Natural History Study
prnewswire.com
SRPT
SLDB
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics
globenewswire.com
ALNY
SRPT
IONS
JAZZ
Sarepta Therapeutics anuncia la convocatoria de solicitudes para la 9º edición anual de Route 79, el programa de becas de Duchenne
businesswire.com
SRPT
Sarepta Therapeutics Announces Call for Applications for the 9 th Annual Route 79, The Duchenne Scholarship Program
businesswire.com
SRPT
Sarepta Therapeutics anuncia la convocatoria de solicitudes para la 9º edición anual de Route 79, el programa de becas de Duchenne
businesswire.com
SRPT